| CAT # | Sunan samfur | Bayani |
| Saukewa: CPD100587 | Phlorizin | Phlorizin, wanda kuma ake magana da shi azaman phloridzin, shine glucoside na phloretin, dihydrochalcone, dangin bicyclic flavonoids, wanda bi da bi shine rukuni na rukuni a cikin nau'ikan phenylpropanoid kirar hanyar tsiro. Phlorizin shine mai hana SGLT1 da SGLT2 saboda yana gasa tare da D-glucose don ɗaure ga mai ɗauka; wannan yana rage jigilar glucose na koda, yana rage adadin glucose a cikin jini. An yi nazarin Phlorizin a matsayin yuwuwar maganin magunguna don nau'in ciwon sukari na 2, amma tun daga lokacin an maye gurbinsa da ƙarin zaɓaɓɓu kuma mafi kyawun analog na roba, kamar canagliflozin da dapagliflozin. |
| Saukewa: CPD0045 | Ipragliflozin | Ipragliflozin, kuma aka sani da ASP1941, mai ƙarfi ne kuma zaɓi mai hana SGLT2 don kula da nau'in ciwon sukari na 2. Jiyya na Ipragliflozin ya inganta sarrafa glycemic lokacin da aka ƙara shi zuwa jiyya na metformin kuma ana iya danganta shi da asarar nauyi da raguwar hawan jini idan aka kwatanta da placebo. Ipragliflozin yana inganta ba kawai hyperglycemia ba har ma da ciwon sukari / kiba mai alaƙa da rashin daidaituwa na rayuwa a cikin nau'in berayen masu ciwon sukari na 2. An amince da shi don amfani a Japan a cikin 2014 |
| Saukewa: CPD100585 | Tofogliflozin | Tofogliflozin, kuma aka sani da CSG 452, mai ƙarfi ne kuma babban zaɓi na SGLT2 inhibitor a ƙarƙashin haɓaka maganin ciwon sukari. Tofogliflozin yana inganta sarrafa glycemic kuma yana rage nauyin jiki a cikin marasa lafiya da ke da nau'in ciwon sukari na 2. Tofogliflozin kashi-dogara yana hana shigar glucose cikin sel tubular. Babban bayyanarwar glucose (30?mM) na 4 da 24?h yana haɓaka haɓakar haɓakar damuwa na oxidative a cikin sel tubular, waɗanda jiyya na tofogliflozin ko wani antioxidant N-acetylcysteine (NAC) ya hana. |
| Saukewa: CPD100583 | Empagliflozin | Empagliflozin, wanda kuma aka sani da BI10773 (sunan ciniki Jardiance), magani ne da aka amince da shi don kula da nau'in ciwon sukari na 2 a cikin manya a cikin 2014. Boehringer Ingelheim da Eli Lilly da Kamfanin ne suka haɓaka shi. Empagliflozin shine mai hana sodium glucose co-transporter-2 (SGLT-2), kuma yana haifar da ciwon sukari a cikin jini don cinye kodan kuma a shafe shi a cikin fitsari. Empagliflozin shine mai hana jigilar sodium glucose co-transporter-2 (SGLT-2), wanda aka samo shi kusan a cikin tubules na kusa da abubuwan nephronic a cikin kodan. SGLT-2 yana lissafin kusan kashi 90 na sake shigar da glucose cikin jini. |
| Saukewa: CPD100582 | Canagliflozin | Canagliflozin (INN, sunan kasuwanci Invokana) magani ne don maganin ciwon sukari na 2. Mitsubishi Tanabe Pharma ne ya haɓaka shi kuma Janssen, wani yanki na Johnson & Johnson ne ya tallata shi a ƙarƙashin lasisi. Canagliflozin shine mai hana nau'in furotin 2 na sodium-glucose transport protein (SGLT2), wanda ke da alhakin aƙalla 90% na sake dawo da glucose a cikin koda. Toshe wannan abin jigilar yana haifar da kawar da glucose na jini ta fitsari. A cikin Maris 2013, canagliflozin ya zama farkon SGLT2 inhibitor da aka yarda a Amurka. |
| Saukewa: CPD0003 | Dapagliflozin | Dapagliflozin, wanda kuma aka sani da BMS-512148, magani ne da ake amfani da shi don kula da nau'in ciwon sukari na 2 da FDA ta amince da ita a cikin 2012. Dapagliflozin yana hana nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in nau'in ciwon sukari na 2 (SGLT2) waɗanda ke da alhakin aƙalla 90% na reabsorption na glucose a cikin koda. Toshe wannan hanyar jigilar kayayyaki yana haifar da kawar da glucose na jini ta fitsari. A cikin gwaje-gwajen asibiti, dapagliflozin ya saukar da HbA1c da 0.6 tare da maki placebo yayin da aka ƙara shi zuwa metformin. |
